Enzalutamide is indicated for the treatment of adult men with:

  • High-risk biochemical recurrent (BCR)* non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable for salvage-radiotherapy as monotherapy or in combination with androgen deprivation therapy (ADT)
  • Metastatic hormone-sensitive prostate cancer (mHSPC) in combination with ADT
  • High-risk** non-metastatic castration- resistant prostate cancer (nmCRPC)
  • Metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of ADT and in whom chemotherapy is not yet clinically indicated
  • mCRPC whose disease has progressed on of after docetaxel therapy

*Defined as prostate specific antigen (PSA) doubling time ≤ 9 months, with PSA ≥1 ng/ml post-prostatectomy (+/- radiotherapy) or ≥2 ng/ml above nadir post-radiotherapy only.

**Defined as baseline prostate-specific antigen (PSA) ≥2 ng/mL and PSA doubling time ≤10 months.1

Reference 1. Enzalutamide SmPC

Hello,

Welcome to Enzalutamide & me, a patient website designed exclusively for people receiving treatment with enzalutamide and their carers and family members. This website is designed to provide you with practical, emotional and educational support throughout your treatment journey with enzalutamide.

Home Hero
home banner mobile

Listening for you

Discover our mindfulness podcasts, created specifically for you to help you relax and manage your condition.

Suggested Learning

Learning tips and tricks to help improve your mental wellbeing with our cognitive behavioural therapy sessions.

Suggested Reading

Take a look at our recent articles on advanced prostate cancer, including articles on how treatments work and additional support for your wellbeing.

Learn more about CBT, and how it can support you on your journey with prostate cancer to manage challenging thoughts and emotions.

introduction to cbt
introduction to cbt mobile

Reporting of side effects

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd. on 0800 783 5018.